TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,226,051 | +20.3% | 2,150,565 | +106.7% | 0.22% | +19.0% |
Q2 2023 | $15,978,947 | -50.7% | 1,040,296 | -27.7% | 0.19% | -57.1% |
Q1 2023 | $32,378,831 | +1488.8% | 1,439,699 | +1385.6% | 0.44% | +1533.3% |
Q4 2022 | $2,037,975 | -69.2% | 96,908 | -63.9% | 0.03% | -70.7% |
Q3 2022 | $6,608,000 | +86.7% | 268,175 | +83.8% | 0.09% | +58.6% |
Q3 2021 | $3,539,000 | – | 145,918 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |